Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia

Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-Endemic Participants in Cambodia

Background:

Mosquito-borne viruses like dengue cause major illness and death worldwide, particularly in Southeast Asia. When mosquitoes deliver a virus into the skin of humans, they also leave saliva. Researchers want to learn more about skin immunity to mosquito saliva. They hope this will help with future vaccines and treatments for these diseases.

Objective:

To compare the early and late innate immune response in the skin of Aedes aegypti bitten versus unbitten skin.

Eligibility:

Healthy people ages 18-45 who live within about 15 km of the study site in Chbar Mon

Design:

Participants will have 3 visits.

The baseline/screening visit will include:

Medical and medication history

Questions about participants demographic information, mosquito biting risk factors, and responses to mosquito or other insect bites

Physical exam

Urine sample for some participants

Mosquito feeding. A feeding device will be placed on the participant s arm for up to 20 minutes. The insects will feed through a mesh on the bottom of the feeding device. Participants may be given standard treatments for any skin reactions.

Blood tests

Four skin biopsies taken from bitten and unbitten skin. Local anesthetic will be administered, and a small tool will be used to remove the participant s skin.

Participants will have a second visit the next day. They will have a physical exam and blood tests. They will have 1 skin biopsy.

Participants will have a final visit about 2 weeks later. They will have a physical exam and blood tests.

During the study, participants will be asked to take measures to prevent more mosquito bites.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Mosquito-borne viruses continue to cause significant global morbidity and mortality, particularly in Southeast Asia. When mosquitoes deliver the virus into the skin of humans while probing for a blood meal, they deposit also saliva, which contains a myriad of pharmacologically active compounds that modulate the host immune system. Little is known about skin immunity to mosquito saliva, particularly in endemic volunteers as most clinical studies are performed in na(SqrRoot) ve individuals who have never or rarely been exposed to a particular mosquito vector. People living in endemic areas have had long-term repeated exposure to these vectors and therefore have different immune response to mosquito saliva, which could interfere with mosquito-borne disease vaccine effectiveness. Characterization of skin immunity via various technical modalities will be important in order to identify critical aspects of the innate and adaptive immune responses after a vector bite.

Here, we will execute a paired study of exposed-unexposed skin to carefully examine the innate and adaptive immune responses in the skin and blood to exposure of the saliva of Aedes aegypti, the mosquito vector of dengue, Zika, and chikungunya viruses. We will enroll 42 participants to undergo vector feeding and give blood samples at baseline and 2 and 14 days later. Additionally, participants will give skin punch biopsy samples of bitten (exposed) and unbitten (unexposed) skin. For analysis, we will group 10-12 participants in each of 4 technical modality cohorts or groups : 1) immunohistochemistry, 2) RNA sequencing, 3) flow cytometry, and 4) T-cell receptor sequencing. With the current rise of vector-borne diseases in the United States and around the world, we hope the results of this study contribute to future vaccine design and clinical development strategies for vector#borne diseases.

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Chbar Mon, Cambodia, 05251
        • Kampong Speu Referral Hoispital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

-Provision of signed and dated informed consent form

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 - 45 years
  • Live within approximately 15 km of study site
  • In good general health as evidenced by medical history
  • Willing to allow biological samples to be stored for future research.
  • A female is eligible for this study if she meets 1 of the following:

    • Of non-childbearing potential (i.e., women who have had a hysterectomy or tubal

ligation or are postmenopausal, as defined by no menses in >=1 year).

--Of childbearing potential but has negative urine pregnancy test on Day 0

  • Agrees to not use scented lotions, deodorants, or topical creams on each feeding day.
  • Agrees to not take aspirin or any other NSAID (ex. ibuprofen) within 7 days of a biopsy.
  • Agrees to not use oral or topical antihistamines or steroid creams or ointments throughout the

study without prior permission of Principal Investigator (PI).

EXCLUSION CRITERIA:

-Any underlying or current medical condition that, in the opinion of the investigator, would

interfere with participation in the study.

-History of severe allergic reaction (including to mosquito or other insect bites) with generalized

urticaria, angioedema, anaphylaxis, anaphylactoid reaction or any other reaction described by

the participant and deemed severe by the PI.

  • Self-reported or known history of alcoholism or drug abuse within 6 months prior to enrollment
  • Self-reported or known history of psychiatric or psychological issues that require treatment and

are deemed by the PI to be a contraindication to protocol participation.

-Any use of medications that affect blood clotting within 3 months or history of abnormal blood

clotting

-History of significant scarring such as keloids after previous biopsies, lacerations, abrasions,

surgeries, or other skin procedures (e.g., cosmetic piercings) that are deemed by the PI to be a

contraindication to protocol participation.

-Pregnant or breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mosquito Feeding
Each participant will receive one mosquito feeding with 5 starved female Aedes aegypti mosquitoes.
Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measurement of Change in Early and Late Innate Immune Responses Using Gene Expression and Flow Cytometry in Participants' Skin
Time Frame: Day 0 timepoints
Measurement of changes in the early and late innate immune response and cellular recruitment in bitten skin versus unbitten skin by: a) immunohistochemistry of target proteins at Day 0 timepoints b) immunophenotyping of innate immune cell subsets in dissociated skin sample at Day 0 timepoints c) determination of cytokine profile in dissociated skin sample supernatant at Day 0 timepoints d) differential cDNA expression prepared from skin RNA and analyzed via RNASeq at Day 0 timepoints
Day 0 timepoints
Measurement of Changes in the Adaptive Immune Response and Cellular Recruitment in the Skin of Bitten Versus Unbitten Skin After Sixth and Final Feeding in Each Vector Group.
Time Frame: Day 2 (48 hr post feeding)
Measurement of changes in the adaptive immune response and cellular recruitment in bitten skin versus unbitten skin by: a) immunohistochemistry of target proteins at Day 2 timepoints b) phenotyping of adaptive immune cell subsets in dissociated skin sample at Day 2 timepoints c) determination of cytokine profile in dissociated skin sample supernatant at Day 2 timepoints d) differential cDNA expression prepared from skin RNA and analyzed via RNASeq at Day 2 timepoints
Day 2 (48 hr post feeding)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Flow Cytometry Analysis of PBMCs Collected Day 0 (Baseline) and Days 2 and 14 After Feeding for Saliva-specific T-cells
Time Frame: Day 14
Describing and understanding cellular immunity to Aedes saliva in heavily exposed individuals will simulate endemic conditions and will inform vaccine design in these target populations.
Day 14

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 27, 2020

Primary Completion (Actual)

April 9, 2021

Study Completion (Actual)

April 9, 2021

Study Registration Dates

First Submitted

April 16, 2020

First Submitted That Met QC Criteria

April 16, 2020

First Posted (Actual)

April 17, 2020

Study Record Updates

Last Update Posted (Actual)

April 12, 2022

Last Update Submitted That Met QC Criteria

March 21, 2022

Last Verified

April 9, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 999920053
  • 20-I-N053

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vector Borne Diseases

Clinical Trials on Mosquito Feeding

3
Subscribe